|Biomerica receives CE European approval
|Biomerica receives CE European approval for new one of a kind simple consumer test to determine allergy to Dogs
The Fortel® Dog Allergy Test is the second test in a planned line of home allergy tests that have laboratory accuracy
Irvine, California – August 23, 2010 -- Biomerica, Inc. (OTC BB: BMRA) announced today that it has introduced a new 15 minute consumer home test to determine allergy to dogs. The Company has just received CE mark approval to market and sell the product directly to consumers through drug stores in the European Union. The product will be marketed under the Fortel® Dog allergy test brand.
Over 80 million people in Europe have some form of allergic disease and the prevalence of the disease is increasing. The annual cost of allergies is estimated to be nearly $7 billion in the United States and accounts for more than 17 million outpatient office visits every year. Allergy is the 5th leading chronic disease in the U.S. among all ages, and the 3rd most common chronic disease among children under 18 years old.
“Imagine being able to screening for allergies in the privacy of your own home. For the first time, European consumers will be able to purchase a test in their pharmacy to screen for allergies to dogs with laboratory accuracy,” said Zackary Irani, CEO of Biomerica. “The CE regulatory approval, which took over one year to obtain, allows us to distribute our product to drugstores and other retailers throughout Europe. We are also working to add additional allergy tests to the Fortel consumer test line of products.”
Biomerica’s Fortel Dog allergy test utilizes an advanced technology that requires only a drop of a person’s blood with results in 15 minutes. The Fortel® Dog Allergy Test is a part of BIOMERICA’s line of easy to use tests designed to detect diseases before they become catastrophic, incurable or costly to treat and is a complement to the Fortel Cat Allergy Test currently being sold in Europe.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices ) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company’s products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses is on products for Diabetes, Gastrointestinal Disease and esoteric testing.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, growth of business, favorable positions, expansion, expected orders, leading market positions, anticipated future revenues or production volume of the Company, success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company’s operating results due to its business model and expansion plans, downturns in international and or national economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company’s dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.